Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing statins and application thereof

A composition and drug technology, applied in the field of medicine, to achieve the effects of enriching existing technology, overcoming adverse reactions, and reducing adverse reactions

Active Publication Date: 2012-04-18
南通金羽禽业发展有限公司
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] All in all, there is currently no very effective drug for the treatment of fatty liver clinically. Therefore, finding effective intervention drugs has very important theoretical significance and application value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing statins and application thereof
  • Composition containing statins and application thereof
  • Composition containing statins and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Treatment of Atorvastatin Calcium / Rimonabant to Nonalcoholic Fatty Liver Model Rats

[0032] (1) Preparation of non-alcoholic fatty liver model rats

[0033] SD rats, male, weighing 220±20g, were modeled by intragastric administration of high-fat emulsion. High-fat emulsion formula: 200g of lard, 100g of cholesterol, 50g of fructose, 50g of sucrose, 10g of bile salt, 10g of sodium glutamate, 150ml of propylene glycol, add a little soil temperature-80, stir well, add distilled water to make up to 1000ml. Except for the rats in the normal control group, the other rats were intragastrically administered the high-fat emulsion for 7 weeks.

[0034] (2) Grouping and administration

[0035] After one week of adaptive feeding, the rats were randomly divided into normal control group, model control group and each administration group. The specific grouping information is shown in the table below, with 10 rats in each group. Except for the normal group, each group wa...

Embodiment 2

[0059] Example 2 The treatment of rosuvastatin calcium / rimonabant on non-alcoholic fatty liver model rats

[0060] (1) Preparation of non-alcoholic fatty liver model rats

[0061] With embodiment 1.

[0062] (2) Grouping and administration

[0063] After one week of adaptive feeding, the rats were randomly divided into normal control group, model control group and each administration group. The specific grouping information is shown in the table below, with 10 rats in each group. Except for the normal group, each group was fed with high-fat emulsion at 9:30 am every day, with a dose of 10ml·kg -1 d -1 . In addition, after 3 days of gavage of the high-fat emulsion, the test substance was gavaged at 14:30 every afternoon for 7 weeks. The test substance and dosage of each group are as follows:

[0064] Normal control group: the same volume of purified water;

[0065] Model control group: the same volume of sodium carboxymethyl cellulose;

[0066] Rosuvastatin group (Rosuv...

Embodiment 3

[0087] Embodiment 3 The treatment of simvastatin, pravastatin sodium or lovastatin compound to non-alcoholic fatty liver model rats

[0088] (1) Preparation of non-alcoholic fatty liver model rats

[0089] With the preparation method of embodiment 1.

[0090] (2) Grouping and administration

[0091] After one week of adaptive feeding, the rats were randomly divided into normal control group, model control group and each administration group. The specific grouping information is shown in the table below, with 10 rats in each group. Except for the normal group, each group was fed with high-fat emulsion at 9:30 am every day, with a dose of 10ml·kg -1 d -1 . In addition, after 3 days of gavage of the high-fat emulsion, the test substance was gavaged at 14:30 every afternoon for 7 weeks. The test substance and dosage of each group are as follows:

[0092] Normal control group: the same volume of purified water;

[0093] Model control group: the same volume of sodium carboxym...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition containing statins and application thereof. The active ingredient of the composition is composed of statins and rimonabant, wherein the statins comprise atorvastatin calcium, simvastatin, pravastatin sodium and rosuvastatin calcium. The pharmaceutical composition provided by the invention can effectively prevent or treat fatty liver.

Description

technical field [0001] The invention relates to a composition containing statins and its application, belonging to the technical field of medicine. Background technique [0002] Statins are hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which block the endogenous cholesterol synthesis rate-limiting enzyme (HMG-CoA) reductase by competitively inhibiting The metabolic pathway of intracellular valonate reduces the synthesis of cholesterol in the cell, thereby stimulating the increase in the number and activity of low-density lipoprotein (LDL) receptors on the surface of the cell membrane (mainly liver cells) and clearing serum cholesterol. increase, decrease in level. Statins can also inhibit the synthesis of apolipoprotein B-100 in the liver, thereby reducing the synthesis and secretion of triglyceride-rich AV and lipoproteins. [0003] Statins are divided into natural compounds (such as lovastatin, simvastatin, pravastatin, mevastatin) and completely synth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/454A61K31/40A61K31/366A61K31/22A61K31/505A61P1/16
Inventor 不公告发明人
Owner 南通金羽禽业发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com